12,372 trials
Metastatic Castration-resistant Prostate Cancer · Metastatic Castration-sensitive Prostate Cancer · Metastatic Prostate Cancer
Primary: Serum Testosterone (ng/dL) Days 9 and 10 Average (Rounded-up), CR-ITT — 1.0000; 1.0000 ng/dL
Cystic Fibrosis
Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 241; 38…
Acute Leukemia · Chronic Myelogenous Leukemia (CML) · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) at One Year — 52.3; 35.5 percentage of participants — p=0.001
Psoriasis
Primary: Area Under the Plasma Concentration Time Curve (AUC) Over the Dosing Interval (AUCtau) Between Week 52 and Week 64 — 5144.40; 5768.45 hour*mcg/mL
Malaria
Primary: Malaria Incidence — 0.0176; 0.0183 Malaria cases per person-week
Clostridium Difficile Associated Disease
Primary: Adjusted Geometric Mean Concentration (GMC) of Clostridium Difficile Toxin A and Toxin B Specific Neutralizing Antibodies at Month 7 for Evaluable Immunogenicity…
Phenylketonuria
Primary: Part 2 Double-blind Phase: Mean Change From Baseline in Blood Phenylketonuria (Phe) Level to Weeks 5 and 6 (Averaged Over a 2-week Period) in Participants With Phe…
Brain Death · Heart Failure
Primary: Heart Transplanted — 230; 223 Participants — p=0.57
Aneurysmal Subarachnoid Hemorrhage
Primary: Occurrence of Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI) From Study Drug Initiation up to 14 Days Post-study Drug Initiation — 32; 35 Participants…
Heart Failure · Heart Failure, Systolic · Erectile Dysfunction
Primary: Erectile Function Score Using Index of Erectile Function (IIEF-15) — 15.1; 12.2 Scores on a scale — p=0.3432
Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
Primary: Clinical Global Impressions- Improvement in Angelman Syndrome (CGI-I-AS) Rating at 12 Weeks — 1; 2; 11; 11 Participants
Huntington Disease · Irritability
Primary: Irritability as Assessed by The Irritability Scale. — 27.5 score on a scale
Spinal Muscular Atrophy
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) by Weight Bracket — 7; 8; 9; 24 Participants
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Primary: Mean Change From Baseline in BCVA at Week 8 — 6.4; 6.5 Letters
Diabetic Macular Edema
Primary: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 for the Study Eye — 10.6; 9.4 Scores on a scale — p=<0.001